The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,204,325 in first-year total cost, median $399,840.
Most frequent study sections
- Special Emphasis Panel[ZAG1 ZIJ-1 (M3)]3
Most frequent institutions
- 5M BIOMED, LLC1
- BOLDEN THERAPEUTICS, INC.1
- NEMALIFE INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | Entrepreneurial development award for a novel Alzheimer's disease therapeutic1R43AG078719-01 | VALAT, ANNE | BOLDEN THERAPEUTICS, INC., RI | $406,466 | ZAG1 |
| 2022 | Highly Sensitive and Robust Blood Test Platform for Screening and Early Detection of Alzheimer's Disease1R43AG078718-01 | LI, YUANCHENGMAO, HUI | 5M BIOMED, LLC, GA | $399,840 | ZAG1 |
| 2022 | High throughput functional screening of anti-sarcopenia therapeutics1R43AG078715-01 | RAHMAN, MIZANUR | NEMALIFE INC., TX | $398,019 | ZAG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.